EXACT Therapeutics and Cordance Medical Announce Early Encouraging Data in Brain Cancer Mice Model

28 Jan 2025 08:00 CET

Oslo, Norway and Mountain View, CA, 28 January 2025. EXACT Therapeutics
(Euronext Growth: EXTX), a clinical-stage precision medicine company, and
Cordance Medical, a pioneer in non-invasive medical technologies for brain
disease treatment, are pleased to announce initial positive results indicating
more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain
tumors of mice inoculated with glioblastoma cancer cells, one of the most
aggressive and hard-to-treat brain cancers. The increased uptake resulted from
combining Exact Therapeutics’ proprietary Acoustic Cluster Therapy (ACT®) with a
device designed by Cordance Medical to deliver ultrasound energy non-invasively
into the brain. The studies were performed at The Arctic University of Norway
and the University Hospital of North-Norway in Tromsø by Dr. Mathias Kranz.

The combination of ACT and the device may offer potential applications across a
wide range of brain diseases, by enabling therapeutic access to large brain
regions. The combined technologies can induce bioeffects, such as temporarily
increasing blood-brain barrier permeability in targeted regions and increasing
the uptake of therapeutic agents. ACT and the device may be utilized for both
diagnostic and targeted therapeutic brain applications. Further experiments are
ongoing to expand the early data, and the results will be submitted for
publication in scientific journals.

“The combination of the Cordance technology and the ACT microcluster technology
from Exact Therapeutics provides exciting possibilities for accessing and
opening larger volumes in the brain without necessarily increasing the focused
ultrasound procedure time or the total amount of ultrasound energy,” said Dr.
Bhaskar Ramamurthy Cofounder and CEO of Cordance Medical.

“These positive results in glioblastoma provide additional early evidence of the
versatility of the noninvasive ACT microcluster technology in cancer therapy.
Oncology is the key focus for Exact Therapeutics, spearheaded by our ongoing
Phase 2 trial in locally advanced pancreatic cancer, which received IND
clearance at the end of 2024.”, said Dr. Per Walday, CEO of Exact Therapeutics.

About Cordance Medical
Cordance Medical specializes in innovative, non-invasive solutions for treating
brain diseases. The company’s flagship NeuroAccess™ platform is designed to
enable precise, targeted treatment options, improving patient outcomes
worldwide.

About Exact Therapeutics
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound and microbubbles to enable targeted drug delivery in
oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be
applied to a wide range of therapeutic agents within oncology and across a
multitude of other indications, including brain diseases. www.exact-tx.com

For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

More information:
Access the news on Oslo Bors NewsWeb site